ストックスクリーナーアプリを入手
1.475
0.68%
0.015
前日終値:
$1.46
開ける：
$1.49
24時間の取引高:
853.54K
Relative Volume:
0.33
時価総額：
$536.01M
収益：
$1.21M
当期純損益:
$-177.12M
株価収益率:
-1.8438
EPS:
-0.8
ネットキャッシュフロー:
$-162.37M
1週間 パフォーマンス:
+2.80%
1か月 パフォーマンス:
+31.25%
6か月 パフォーマンス:
+187.05%
1年 パフォーマンス:
-17.88%
1日の値動き範囲:
$1.47
$1.51
1週間の範囲:
$1.40
$1.66
52週間の値動き範囲:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
名前
Lexicon Pharmaceuticals Inc
セクター
電話
(281) 863-3000
住所
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.475 | 530.56M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.87 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.42 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.86 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.20 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
315.17 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-30 | 開始されました | Leerink Partners | Outperform |
| 2023-03-07 | 開始されました | Jefferies | Hold |
| 2022-08-12 | 開始されました | Piper Sandler | Overweight |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-01-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-18 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-12-11 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2019-11-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-11 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-07-29 | ダウングレード | Stifel | Buy → Hold |
| 2019-03-25 | アップグレード | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 繰り返されました | Stifel | Buy |
| 2018-02-23 | ダウングレード | Needham | Buy → Hold |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-01 | 繰り返されました | Wedbush | Outperform |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-05 | 繰り返されました | Wedbush | Outperform |
| 2016-08-02 | 開始されました | Citigroup | Buy |
| 2016-03-02 | 繰り返されました | Wedbush | Outperform |
| 2015-11-09 | 繰り返されました | Wedbush | Outperform |
| 2015-09-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2015-09-18 | ダウングレード | Gabelli & Co | Hold → Sell |
| 2015-08-10 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times
Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Lexicon Pharmaceuticals Inc. building a consolidation baseMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat
Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat
Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus
Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛
Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com
Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Is Lexicon Pharmaceuticals Inc. stock bottoming out2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price actionGap Up & High Accuracy Investment Signals - newser.com
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st
Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat
What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in
Lexicon reports FDA's decision to extend review period for Zynquista - MSN
Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia
Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com
Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus
Lexicon Pharmaceuticals Inc (LXRX) 財務データ
収益
当期純利益
現金流量
EPS
Lexicon Pharmaceuticals Inc (LXRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
3.56%
0.21%
大文字化:
|
ボリューム (24 時間):